Although poor solubility, low and variable oral bioavailability, and incomplete pharmacokinetic and safety data currently limit immediate clinical application, recent progress in nanodelivery systems and mechanistic understanding, together with opportunities for biomarker-guided patient selection and rational combination therapy, supports an optimistic view that HF may ultimately evolve into a clinically useful option for selected patients with treatment-refractory, p53 wild-type malignancies. Here, TP53 is linked to hydrops fetalis.